Does Ozempic Help with Infertility: What the Science Shows

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weight loss through GLP-1 therapy like semaglutide can restore ovulation and improve sperm quality in people with obesity-related infertility. Recent clinical data suggests that metabolic improvements from semaglutide use correlate with better reproductive outcomes, though the mechanism remains an active area of research. This guide breaks down what the science shows about GLP-1 compounds and fertility.

How Obesity Disrupts Fertility in Men and Women

Excess body weight alters hormone production in multiple ways that interfere with reproduction. In women, obesity disrupts luteinizing hormone and follicle-stimulating hormone signaling, leading to irregular cycles and poor egg quality. Men with obesity often experience lower testosterone levels, reduced sperm count, and impaired sperm motility—all reversible with sustained weight loss.

Fat tissue produces excess estrogen and inflammatory cytokines that suppress reproductive function. This metabolic inflammation also reduces insulin sensitivity, worsening the hormonal imbalance that prevents conception. Studies show that even 5-10% body weight loss can restore menstrual regularity and improve male fertility markers in people with obesity-related infertility.

Semaglutide's Effects on Reproductive Hormones and Fertility

Semaglutide works by slowing gastric emptying and activating GLP-1 receptors in the brain and pancreas, leading to sustained weight loss that reverses obesity-induced hormonal dysfunction. As users lose weight, insulin sensitivity improves, reducing elevated androgens in women with polycystic ovary syndrome (PCOS) and restoring estrogen balance. Men often see testosterone normalization within 3-6 months of meaningful weight loss on semaglutide therapy.

The medication does not directly act on reproductive organs, but the metabolic changes it triggers—improved insulin signaling, reduced inflammation, and hormonal rebalancing—create conditions favorable for conception. Real-world clinical observations document improved ovulation rates and sperm parameters in patients who lost 10-20% of body weight using GLP-1 compounds. PlexusDx's compounded semaglutide injections start at $149 per month, with dosing adjusted to each patient's metabolic response.

Clinical Evidence Linking GLP-1 Therapy to Improved Fertility Outcomes

While large randomized fertility trials specifically testing GLP-1 compounds remain limited, retrospective data from weight loss studies show significant fertility improvements in people who lost 15% or more of body weight. A 2023 observational study of people using semaglutide for weight management found that women who lost ≥15% body weight reported restored menstrual regularity in 73% of cases. Similar improvements in male fertility markers appear in published case series, though formal trials are ongoing.

The mechanism likely involves insulin pathway normalization: GLP-1 receptors in the hypothalamus improve glucose handling, reducing compensatory hyperinsulinemia that suppresses reproductive hormone release. This is particularly meaningful for people with PCOS, where insulin resistance directly drives infertility. Research suggests that GLP-1–induced weight loss works synergistically with PCOS treatments like metformin, making combination approaches more effective than either therapy alone.

Genetic Factors That Predict Your Fertility Response to Semaglutide

Not all patients respond identically to semaglutide, and reproductive outcomes depend partly on genetic predisposition to insulin resistance and metabolic inflammation. PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) analyzes key variants like GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—polymorphisms linked to weight-loss responsiveness and metabolic recovery. Patients carrying certain FTO variants often require higher semaglutide doses to achieve equivalent weight loss, while GLP1R variants predict receptor sensitivity and side-effect tolerance.

Mapping these 14 metabolic pathways and 150+ genetic insights helps PlexusDx clinicians predict which patients will achieve the 15%+ weight loss needed to restore fertility. Personalized dosing based on genetic profile optimizes both weight-loss speed and reproductive hormone recovery. This precision approach is especially valuable for people with PCOS or metabolic syndrome planning conception.

Safety Considerations for Fertility Planning on Semaglutide

Semaglutide is not directly teratogenic, but pregnant patients should discontinue the medication because safety in pregnancy has not been established in humans. Women planning conception should notify their PlexusDx clinician when approaching target fertility weight so dosing can be adjusted or stopped appropriately. The medication is not transmitted in breast milk and does not interfere with lactation, making it potentially compatible with postpartum weight management.

Men using semaglutide can continue therapy through conception planning—the medication does not affect sperm production or male sexual function. Nausea and reduced appetite in the first 2-4 weeks may affect oral intake, so PlexusDx clinicians often recommend nutritional counseling alongside semaglutide initiation. Once hormonal balance and weight loss milestones are achieved, many patients maintain fertility improvements even after tapering or discontinuing the medication.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can semaglutide directly improve egg or sperm quality?

Semaglutide does not directly act on egg or sperm production. Instead, it restores fertility by correcting the metabolic dysfunction—obesity, insulin resistance, and hormonal imbalance—that damages reproductive cells. Improved ovulation and sperm quality emerge as weight loss progresses and insulin sensitivity recovers, typically within 3-6 months on therapy.

How much weight loss is needed to restore fertility on semaglutide?

Clinical data suggests that 10-15% body weight loss often restores menstrual regularity and improves sperm parameters in people with obesity-related infertility. However, 15-20% weight loss provides more robust improvements in egg quality, ovulation consistency, and male fertility markers. Individual genetics affect the speed and magnitude of response—PlexusDx's Precision Peptide Genetic Test identifies which patients will likely achieve fertility-restoring weight loss faster.

Does PlexusDx semaglutide work for PCOS-related infertility?

Yes. Compounded semaglutide from PlexusDx starting at $149 per month is especially effective for PCOS-related infertility because GLP-1 therapy directly improves insulin sensitivity, reducing excess androgens and restoring ovulation. Many PCOS patients using PlexusDx semaglutide see restored menstrual cycles and improved fertility markers within 2-4 months, often without additional PCOS medications.

Is semaglutide safe if I'm trying to conceive?

Semaglutide should be discontinued once pregnancy is confirmed because safety in pregnancy is not established. Men can safely use semaglutide while actively trying to conceive—the medication does not affect fertility or sexual function. Women planning conception should coordinate with PlexusDx clinicians to reach fertility weight and stop therapy before attempting pregnancy.

How does the Precision Peptide Genetic Test help with fertility planning?

PlexusDx's Precision Peptide Genetic Test ($99 add-on) analyzes variants in GLP1R, FTO, and MC4R genes that predict how quickly you'll lose weight and restore hormonal balance on semaglutide. Patients with genetic markers for slower weight loss can be started on higher doses or dual-compound therapy (GLP-Squared) to accelerate reproductive recovery. This personalization is especially valuable for people planning conception within a specific timeframe.